15 active
/
39 total (since 2015)
4
Phase 1 Active
13 total
7
Phase 2 Active
13 total
9
Phase 3 Active
21 total
1
Phase 4 Active
3 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Chiesi Farmaceutici S.p.A. 3 1 0
Amicus Therapeutics 2 3 0
Sanofi 2 0 1
4D Molecular Therapeutics 2 0 0
Idorsia Pharmaceuticals Ltd. 1 2 0
Takeda 1 1 1
UniQure Biopharma B.V. 1 0 0
Guangzhou Jiayin Biotech Ltd 1 0 0
AceLink Therapeutics, Inc. 1 0 0
ISU Abxis Co., Ltd. 1 0 0
Protalix 0 3 1
NCT05206773 ACTIVE NOT RECRUITING
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
Sanofi n=122
NCT03614234 ACTIVE NOT RECRUITING
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
Chiesi Farmaceutici S.p.A. n=29
NCT06904261 RECRUITING
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
Amicus Therapeutics n=8
NCT04020055 ACTIVE NOT RECRUITING
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
Amicus Therapeutics n=14
NCT06328608 RECRUITING
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Chiesi Farmaceutici S.p.A. n=22
NCT05710692 RECRUITING
Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
Chiesi Farmaceutici S.p.A. n=16
NCT03737214 ACTIVE NOT RECRUITING
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
Idorsia Pharmaceuticals Ltd. n=107
NCT05280548 ACTIVE NOT RECRUITING
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
Sanofi n=104
NCT06081062 RECRUITING
Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
ISU Abxis Co., Ltd. n=24
NCT05843916 COMPLETED
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease
Bio Sidus SA n=20
NCT04049760 COMPLETED
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
Amicus Therapeutics n=16
NCT03566017 COMPLETED
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
Chiesi Farmaceutici S.p.A. n=97
NCT04974749 COMPLETED
A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease
Takeda n=20
NCT03425539 COMPLETED
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
Idorsia Pharmaceuticals Ltd. n=118
NCT02795676 COMPLETED
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
Protalix n=78
NCT03180840 COMPLETED
Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks
Protalix n=30
NCT03018730 COMPLETED
Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
Protalix n=22
NCT03500094 COMPLETED
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)
Amicus Therapeutics n=22
NCT02194985 COMPLETED
Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
Amicus Therapeutics n=84
NCT02921620 WITHDRAWN
Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease
Protalix
Data: ClinicalTrials.gov